These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus]. Escalada FJ Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458 [TBL] [Abstract][Full Text] [Related]
4. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus]. Escalada FJ Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836 [TBL] [Abstract][Full Text] [Related]
5. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Muskiet MHA; Tonneijck L; Smits MM; van Baar MJB; Kramer MHH; Hoorn EJ; Joles JA; van Raalte DH Nat Rev Nephrol; 2017 Oct; 13(10):605-628. PubMed ID: 28869249 [TBL] [Abstract][Full Text] [Related]
6. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Stonehouse A; Okerson T; Kendall D; Maggs D Curr Diabetes Rev; 2008 May; 4(2):101-9. PubMed ID: 18473757 [TBL] [Abstract][Full Text] [Related]
7. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Girard J Diabetes Metab; 2008 Dec; 34(6 Pt 1):550-9. PubMed ID: 19036624 [TBL] [Abstract][Full Text] [Related]
8. [Glucagon-like peptide-1 based therapy for type 2 diabetes]. Yu BS Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):669-71. PubMed ID: 17217659 [No Abstract] [Full Text] [Related]
9. [Incretin strategy in the treatment of type 2 diabetes mellitus--DPPIV--editorial]. Rybka J Vnitr Lek; 2007 Sep; 53(9):934-5. PubMed ID: 18019660 [No Abstract] [Full Text] [Related]
10. Glucagon-like peptide 1 based therapy for type 2 diabetes. Yu BS; Wang AR World J Pediatr; 2008 Feb; 4(1):8-13. PubMed ID: 18402245 [TBL] [Abstract][Full Text] [Related]
11. Emerging concepts in the pathophysiology of type 2 diabetes mellitus. Surampudi PN; John-Kalarickal J; Fonseca VA Mt Sinai J Med; 2009 Jun; 76(3):216-26. PubMed ID: 19421965 [TBL] [Abstract][Full Text] [Related]
12. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471 [TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide 1 in health and disease. Andersen A; Lund A; Knop FK; Vilsbøll T Nat Rev Endocrinol; 2018 Jul; 14(7):390-403. PubMed ID: 29728598 [TBL] [Abstract][Full Text] [Related]
18. Incretin-based therapies: a clinical need filled by unique metabolic effects. Drucker DJ Diabetes Educ; 2006; 32 Suppl 2():65S-71S. PubMed ID: 16554430 [No Abstract] [Full Text] [Related]
19. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715 [TBL] [Abstract][Full Text] [Related]
20. Will Gut Microbiota Help Design the Next Generation of GLP-1-Based Therapies for Type 2 Diabetes? Claus SP Cell Metab; 2017 Jul; 26(1):6-7. PubMed ID: 28683295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]